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Abstract. Preventive chemotherapy with praziquantel for schistosomiasis morbidity control is commonly done by
mass drug administration (MDA). MDA regimen is usually based on prevalence in a given area, and effectiveness is
evaluated by decreases in prevalence and/or intensity of infection after several years of implementation. Multiple studies
and programs now ﬁnd that evenwithin well-implemented, multiyear, annual MDA programs there often remain locations
that do not decline in prevalence and/or intensity to expected levels. We term such locations “persistent hotspots.” To
study and address persistent hotspots, investigators and neglected tropical disease (NTD) program managers need to
deﬁne them based on changes in prevalence and/or intensity. But how should the data be analyzed to deﬁne a persistent
hotspot? We have analyzed a dataset from an operational research study in western Tanzania after three annual MDAs
using four different approaches to deﬁne persistent hotspots. The four approaches are 1) absolute percent change in
prevalence; 2) percent change in prevalence; 3) change in World Health Organization guideline categories; 4) change
(absolute or percent) in both prevalence and intensity. We compare and contrast the outcomes of these analyses. Our
intent is to showhow the samedataset yieldsdifferent numbersof persistent hotspotsdependingon theapproachused to
deﬁne them. We suggest that investigators and NTD program managers use the approach most suited for their study or
program, but whichever approach is used, it should be clearly stated so that comparisons can be made within and
between studies and programs.
INTRODUCTION
Global efforts to control morbidity due to schistosomiasis
were codiﬁedby theWorldHealthAssembly (WHA)Resolution
54.191 in 2001. Since then, these efforts have largely rested on
preventive chemotherapy (PC) with praziquantel (PZQ), often
delivered through mass drug administration (MDA) either in
school-based or community-wide programs.2–4 These pro-
grams have often been implemented by national neglected
tropical disease (NTD) control programs partnered with dif-
ferent enabling organizations through bilateral arrangements.
As increasing numbers of nationalNTDcontrol programshave
scaled-up MDA, and major PZQ supplies (both donated and
purchased) have been announced andprovided, theWHAhas
approved two more resolutions (WHA 65.21 and 66.12) in
2012 and 2014, respectively,5,6 that urge programs, where
appropriate, to move from the goal of morbidity control to the
extended goal of elimination of schistosomiasis as a public
health problem, with the eventual objective of interrupting
schistosomiasis transmission.
Over the last 15 years, MDA using PZQ has substantially
lowered both prevalence and intensity of infection in many
areas.7,8 However, some subareas, at times as focal as an
individual village, fail to substantially decrease their preva-
lence and mean intensity of Schistosoma infections despite
several years of well-implemented MDA coverage.9 Fre-
quently, it is onlywhenaprogramor study “goes to scale,” and
only if there is sufﬁciently thorough monitoring, that such fo-
cal, village-to-village differences are observable.
The Schistosomiasis Consortium for Operational Research
and Evaluation (SCORE; https://score.uga.edu/) has been
conducting large-scale operational research into morbidity
control. Its aim is to determine the most effective means of
providing PC through MDA when delivered either through
community-wide treatment (CWT) or through school-based
treatment (SBT).10 In the performance of these large (75–150
villages) SCOREmultiyear studies, we have identiﬁed villages
that continue to have high prevalence and intensity despite 3
or 4 years of annual MDA. By contrast, other villages, some
quite nearby, show reductions to expected low levels of
Schistosoma infection prevalence and intensity. To better
understand the reasons that some villages fail to decline in
prevalence and intensity and to determine whether these
“persistent hotspots” might be able to be identiﬁed after 1 or
2 years of MDA, precise deﬁnitions for persistent hotspots
need to be applied across all such studies and programs.
Clear deﬁnitions will be important in considering whether in-
fection in persistent hotspots can be substantially reduced,
either by enhancingMDA efforts alone or with the introduction
of additional control measures.
The intention of this article is to present possible ap-
proaches to operationally deﬁne persistent hotspots, using
data from one of the SCORE country studies (Tanzania) to
illustrate the suggestedoptions. This dataset is representative
of the variability of response to annual MDAs that can be seen
in multiple other SCORE studies. Their particular variations in
MDA response will be addressed in subsequent articles. We
discuss the potential use of different deﬁnitions for those in-
vestigators andNTDprogrammanagers who are now seeking
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to understand and address persistent hotspots. The term,
persistent hotspot, as it is usedhere, requires that locationsdo
not decline as expected in prevalence and intensity in the face
of multiyear MDA. This means that by this deﬁnition a per-
sistent hotspot is only deﬁned after an intervention; simply
starting at high infection prevalence or intensity before control
interventions is not sufﬁcient for a location to be termed a
persistent hotspot. The examples used in this analysis are
from locations that have started with relatively high preva-
lence. However, other SCORE studies in areas with lower
prevalence also demonstrate variability in response to multi-
yearMDA, andsomeof the sameapproachesdescribedcould
be applied to those areas as they move beyond morbidity
control toward elimination of schistosomiasis.
METHODS
Data from the multivillage SCORE Schistosoma mansoni
control study based in Mwanza, Tanzania were used to eval-
uate different approaches to deﬁning persistent hotspot lo-
cations observable after 3 years of annual MDA. A description
of the overall study, its methods, and baseline data has been
published.10 Brieﬂy, the Tanzania “Gaining Control” Sm2
study compared annual MDA by CWT and annual MDA by
SBT delivered either every year or every other year and was
designed to be done in villages with baseline prevalence ³
25%. In a few locations, starting prevalence was < 25%. For
the purposes of the calculations presented, prevalence and
intensity are basedonour data from9- to 12-year-old children,
and MDA coverage is deﬁned in both CWT and SBT locations
as the proportion of school-aged children (SAC) who had re-
ceived treatment with PZQ in that round of treatment.
For the purposes of this study, we included only villages or
schools in those arms that received MDA every year, whether
CWTor SBT, or a serial combination of these two approaches.
These correspond to Year 1 and Year 4 data from the 74 vil-
lages in Arms 1, 2, and 4 previously described in the protocol
paper.10 Prevalence and intensity data were collected in
cross-sectional testingof 9- to12-year-old children each year,
just before that year’s scheduled MDA.
Year 4 data (collected after 3 years of MDA) were used to
assess four possible approaches to deﬁning persistent hot-
spots. Villages that did not meet the deﬁnition for persistent
hotspots were said to have had meaningful, operationally
acceptable declines in prevalence and/or intensity. As seen
below, for the purposes of this exercise, the thresholds used
to evaluate the methods described are set arbitrarily. For
purposes of our analysis, infection intensity was explored in
two ways—1) when calculated among all children who were
tested (village-level intensity) and 2) when calculated only for
those with Schistosoma egg-positive specimens.
Approach 1. Absolute change in prevalence fromYear 1
to Year 4 (prevalence Year 4 minus prevalence Year 1).
Perhaps the simplest approach was based on calculating the
absolute change in prevalence rate from before to after in-
tervention, i.e., the starting prevalence minus the prevalence
after a given number of rounds of annual MDA. However,
because this deﬁnition does not adjust for starting prevalence,
it masks important differences in the endpoints considered
signiﬁcant. For example, a 20% decrease in prevalence in a
location having a starting prevalence of 40%means a decline
to 20% prevalence, whereas in a location with a starting
prevalence of 80%, a 20% prevalence reduction would result
in the community remaining at very high prevalence of 60%.
Approach2.Relativepercent change inprevalence from
Year 1 to Year 4 [(prevalence Year 4 minus prevalence
Year 1/prevalence Year 1) × 100].A second approachwould
be to determine the relative percent change in prevalence,
regardless of starting prevalence. Using this method, the
starting prevalence would inﬂuence the level of decline, such
that going from 80% to 60% would be a 25% drop in preva-
lence, whereas going from40% to 20%would be classiﬁed as
a 50% decline in prevalence.
Approach 3. Change in World Health Organization
(WHO) risk categories (‡ 50%, 10–49%, and < 10% prev-
alence, as used in their MDA guidelines. A third approach is
to incorporate the current WHO guideline thresholds,11 which
deﬁne prevalence of ³ 50%as high risk, 10–49%asmoderate
risk, and < 10% as low risk, for purposes of selecting MDA
treatment frequency and coverage in controlling morbidity
due to Schistosoma infection. By using this method, a
“meaningful decline in prevalence” would require prevalence
to change from one category to a lower category. Thus, a
change after 3 years of MDA from 55% to 45% would be
considered a meaningful decline, whereas a community
moving from45%to15%prevalencewouldbe categorized as
a persistent hotspot.
Approach 4. Combined change in both prevalence and
mean intensity of infection from Year 1 to Year 4. A fourth
approach used both prevalence and intensity measurements
to deﬁne persistent hotspots. In the examples provided, in-
tensity of S. mansoni infection refers to a person’s mean eggs
per gramof stoolmeasured in standardKato-Katzmicroscopy
from 3 day’s specimens, two slides per specimen. In the Re-
sults, we provide examples using either the absolute changes
in prevalence and intensity or the relative changes in preva-
lence and intensity. These ﬁndings are illustrated using a four-
quadrant box. The respective quadrants contain locations
where 1) the prevalence and mean intensity both increased;
2) the prevalence increased and intensity decreased; 3) the
prevalence decreased and intensity increased; and 4) the
prevalence and intensity both decreased.
Coverage is important in determiningwhether a location is a
persistent hotspot or the eligible population was simply not
adequately treated. Therefore, we conducted our analyses in
two ways—the ﬁrst including all locations and the second
including only those locations where adequate coverage was
obtained. For the present analysis, adequate coverage in both
SBT andCWTvillageswas deﬁned as ³ 50%coverage of SAC
during the ﬁrst year ofMDAand ³75% in all subsequent years.
Theagreementbetweencategorizationderivedby thedifferent
approaches was assessed using kappa statistic. Kappa values
were interpreted as poor (< 0.20), fair (0.21–0.40), moderate
(0.41–0.60), substantial (0.61–0.80), and perfect (0.81–1.00).12
RESULTS
Identiﬁcation of persistent hotspots in the test dataset
from SCORE’s study in Tanzania, using each of the four
methods considered. Approach 1. Absolute change in
prevalence from Year 1 to Year 4 (prevalence Year 4 minus
prevalence Year 1). When we deﬁned a persistent hotspot as a
place with a 30% or less decrease in prevalence, 37 of the 74
schools/villages (50%) met this criterion (Figure 1).
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Of note, the starting prevalencewas > 30% for 17 locations,
10–30% for 16, and < 10% for 4 (Figure 2). It is obvious that a
location that started below 30% prevalence could not de-
crease its prevalence value more than 30% and would be
automatically called a persistent hotspot under Approach 1. In
Figure 2, the thirty percent prevalence threshold is indicated
by the dashed line.
Approach 2. Relative percent change in prevalence from
Year 1 to Year 4 [(prevalence Year 4 minus prevalence Year
1/prevalence Year 1)× 100]. For thismethod,which took starting
prevalence into consideration, we chose an arbitrary level of
< 40% relative change to deﬁne a persistent hotspot. By this
approach, 22 locations—30% of the test dataset—were
classiﬁed as persistent hotspots (Figure 3). Using this
method, locations that started out at a low prevalence could
either be categorized as persistent hotspots or as adequately
responding sites.
Fewer locations were deﬁned as persistent hotspots by
Approach 2 as compared with Approach 1 (22 versus 37,
respectively). All but two locations that were identiﬁed as
persistent hotspots by Approach 2 were also identiﬁed as
persistent hotspots by Approach 1. These two locations both
had starting prevalences of more than 90% and decreased to
just < 60% by Year 4. So, although the prevalences in these
two locations decreased by more than 30% in absolute terms
(“adequate” under Approach 1), they remained quite high,
even after 3 years of MDA, with less than a 40% relative re-
duction in prevalence (Approach 2) during intervention.
Seventeen villages that were classiﬁed as persistent hot-
spots by Approach 1 were reclassiﬁed as declining by Ap-
proach 2. Most of these villages had a starting prevalence of
< 30%, which means they had been automatically classiﬁed
as persistent hotspots under Approach 1.
Approach 3. Change in WHO risk categories ( ³ 50%,
10–49%, and < 10% prevalence, as used in their MDA
guidelines. The WHO recommended treatment strategy for
schistosomiasis for achieving morbidity control classiﬁes
communities into high risk (³ 50%), moderate risk (10–49%),
and low risk (< 10%) based on prevalence. For S. mansoni-
endemic areas, these thresholds are based on infection de-
tection using the Kato-Katz thick smear fecal microscopy
assay. In Approach 3, we deﬁned a location that remained
within its riskgroupafter several roundsofMDAasapersistent
hotspot, whereas movement to a lower risk group classiﬁed it
as a declining location with adequate response. For example,
a location starting at ³ 50%prevalence that remains at ³ 50%
prevalence would be classiﬁed a persistent hotspot, whereas
a location that fell to < 50% prevalence would be said to be
declining, by virtue of moving to a lower prevalence category.
For locations starting at 10–49% prevalence, persistent hot-
spots would be those that remain at ³ 10%. Finally, for low-
prevalence locations (< 10%), we arbitrarily chose a separate
cutoff for response, in which a declining village would be one
that fell to < 3% prevalence.
Using Approach 3 to deﬁne persistent hotspots for the 74
locations in the dataset, 19 (about a fourth) were classiﬁed as
persistent hotspots. Of the 43 communities starting in the
high-risk category (³ 50% starting prevalence), 30 (repre-
senting 70% of the dataset) changed to a lower-prevalence
category and were classiﬁed as declining locations. Seven
locations (17%) did not change to a lower-risk category
(Table 1) and were therefore categorized as persistent
FIGURE 1. Histogram of the absolute change in S. mansoni preva-
lence after 4 years ofmass drug administration in 74 villages in Tanzania.
The dotted rectangle indicates persistent hotspots as determined by
Approach 1.
FIGURE 2. Change in prevalence ofS.mansoni fromYear 1 to Year 4 in the 37 Tanzanian study villages thatmet the criteria for persistent hotspot
using Approach 1. Dashed line indicates 30% prevalence.
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hotspots. Of note, a hypothetical location that decreased in
prevalence from 50% to just 49%after several years of annual
MDAwould not be classiﬁed as a persistent hotspot using this
approach. Of the 27 locations that started as moderate-risk
communities, 10 (about a third) were classiﬁed by Approach 3
as persistent hotspots, whereas the rest were classiﬁed as
declining locations. Despite prevalence eligibility surveys
having been done before categorization of the communities,
four of 74 locations were subsequently found to be low-risk
communities at the start of the studyand twoof thosedeclined
to < 3%.
Approach 4. Combined change in both prevalence and
village-level mean intensity of infection from Year 1 to Year 4:
both as absolute change and percent change. This approach
of categorizing persistent hotspots takes into account both
the change in prevalence and the change in intensity as de-
termined by the Kato-Katz stool microscopy assay. In this
demonstration, we have analyzed both the absolute and
the relative (percent) change in prevalence and intensity in
Figure 4 and in Figure 5, respectively. By graphing the change
in intensity on the x axis and the change in prevalence on the y
axis and then constructing quadrant lines to deﬁne arbitrary
cutoff points, it is possible to assign treated communities to
categorical quadrants to classify how they responded to the
intervention by adequately decreasing (or not) in both preva-
lence and intensity.
Wearbitrarily set thequadrant lines in Figure 4 so that a 30%
decrease in absolute prevalence (as in Approach 1) and an
absolute decrease in village-level mean intensity of 50 eggs
per gram would qualify a location as declining (lower left
quadrant). Using these cutoffs, 29 locations (39%) fall in the
upper-right quadrant and are deﬁned as persistent hotspots.
Nine locations (12%) declined more than 30% in prevalence
but did not decrease in intensity by 50 eggs per gram of stool
(lower right quadrant) and could also be considered as per-
sistent hotspots by this approach although they would be
considered declining locations by Approach 1.
When only S. mansoni egg-positive study participants were
used to calculate mean intensity and the observed changes in
intensity, 26 locations (35%) were deﬁned as persistent hot-
spots compared with the 29 locations using the village-level
mean intensity. The latter metric is considered to relate to
changes in overall contamination potential within a given vil-
lage, whereas the former relates to average individual infec-
tion levels and may be a better indicator of personal risk for
morbidity.
For the ﬁgure depicting relative changes in prevalence and
intensity (Figure 5), we arbitrarily set the quadrant lines so that
a 40%decrease in relative prevalence (as in Approach 2) anda
50%percent decrease in village-level intensitywould qualify a
location as declining (lower-left quadrant). Using these cut-
offs, 14 locations (19%) fall in the upper-right quadrant andare
deﬁned as persistent hotspots, as opposed to Figure 4, where
using absolute changes classiﬁed 29 locations (39%) as per-
sistent hotspots.
Using either approach to assess changes in intensity
(Figure 4or Figure 5), it is clear thatwhere onesets thearbitrary
cutoffs for both prevalence and intensity can make a major
FIGURE 3. Approach2hotspots:Prevalence inYear 4andYear1, andpercent change inprevalenceamongTanzanianvillageswith<40%relative
decrease in S. mansoni prevalence.
TABLE 1
Classiﬁcation of 74 Tanzanian villages using the criterion of failure to move to a lower WHO risk category as the deﬁnition of a persistent hotspot
Prevalence in Year 4
Total³ 50% 10–49% 3 –< 10% < 3%
Prevalence in Year 1 ³ 50% 7 30 6 – 43
10–49% 0 10 17 – 27
< 10% 0 0 2 2 4
Total 7 40 25 2 74
Persistent hotspots are indicated in boldface. WHO = World Health Organization.
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difference in how locations are categorized, whether as
meaningfully declining or as persistent hotspots. A shift in
either parameter changes the quadrant-based-assigned cat-
egories considerably.
Comparison of ﬁndings using different approaches.We
used kappa statistics to evaluate the agreement among
the various response classiﬁcation approaches that we
had developed. Table 2 illustrates concordance between
FIGURE 4. Absolute change in prevalence of S. mansoni from Year 1 to Year 4 in 74 Tanzanian study villages, plotted against absolute change in
village-level mean intensity (eggs per gram).
FIGURE 5. Relative change in prevalence of S. mansoni from Year 1 to Year 4 in 74 Tanzanian study villages, plotted against relative change in
village-level mean intensity (eggs per gram).
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Approaches 1 and 3, and Table 3 illustrates concordance
between Approaches 2 and 3.
The kappa statistic measuring the enter-rater agreement
between Approach 1 and Approach 3 is 0.35. Thus, there is
only fair agreement between these two classiﬁcation systems.
This discordance between Approach 1 and Approach 3
comes about because some locations decreased in preva-
lence by > 30% but stayed in the same risk category, and
conversely, some villages decreased in prevalence by < 30%
but changed treatment categories. Some discordance also
comes about because villages with a starting prevalence of
< 30% are automatically classiﬁed as persistent hotspots
under Approach 1 regardless of how much their prevalence
changed with multiple MDAs.
The comparison of classiﬁcations by Approaches 2 and 3 is
seen in Table 3, which has a kappa statistic of 0.63, indicating
substantial agreement between these two approaches.
The discordance between Approach 2 and Approach 3,
although less than between Approach 1 and Approach 3,
occurred because some locations showed percent decreases
inprevalenceof >40%but remained in the same risk category,
and conversely, some locations decreased in prevalence by
< 40% but changed risk categories.
Impact of coverage on designation as persistent
hotspot locations. Poor coverage is likely to be among the
ﬁrst factors to evaluate when some villages fail to decline
meaningfully in prevalence. In SCORE studies, adequate
coverage was deﬁned as 50% of SAC treated in Y1 and 75%
SAC treated in subsequent years, and this is the working
deﬁnition used in the coverage impact analyses presented
below. Table 4 shows that only 29 of the 74 locations in the
current dataset achieved adequate coverage by this deﬁni-
tion. For Arm 1 (CWT all 3 years), only 4 of the 24 villages were
classiﬁed as having received adequate coverage.
However, there was no correlation in our Tanzania village
dataset between having inadequate coverage (by the deﬁni-
tion used in these studies: > 50% Year 1 and > 75% sub-
sequent years) and being categorized as a persistent hotspot
by Approaches 1, 2, 3, or 4 (Supplemental Tables 1 –5). In fact,
many persistent hotspots had adequate coverage, and
conversely, many locations that declined in prevalence had
“inadequate” coverage, as previously deﬁned. This then
points to the local inﬂuence of other possible factors, such as
those involved in deﬁning the area’s force of transmission, as
more likely to be responsible for the variation seen in response
to multiple rounds of MDA.
DISCUSSION
Schistosoma transmission and the associated prevalence
of schistosomiasis can be highly focal, even in areas consid-
ered to be broadly endemic. In many areas at risk, prevalence
and intensity levels vary substantially between relatively close
village locations.13 Such focal distribution is attributed to the
nature of the parasite’s life cycle, which requires a concen-
tration of speciﬁc vector snails in combination with poor
sanitation tomaintain continued high levels of transmission.14
Despite this well-known problem, many national NTD control
programs rely on broad-based implementation of MDA pro-
grams with PZQ to control infection. However, as our experi-
ence has shown, implementation of a “standard” MDA
programcan have verymixed results from location to location.
Reliance on MDA for control of morbidity due to schisto-
somiasis is in large part based on long-standing experience
with programs such as that for lymphatic ﬁlariasis (LF). In that
program, treatment of infection is highly effective in inter-
rupting transmission by the killing of microﬁlariae. In such
cases, focal hotspots are less likely to develop than is the case
for schistosomiasis because MDA for LF clearly decreases
local LF transmission.15 For Schistosoma spp. infections,
human reinfection can occur almost immediately after treat-
ment if a person enters water containing infected snails. This
means that although antischistosomal MDA can serve as a
form of schistosomiasis morbidity control, its ability to mark-
edly reduce prevalence (when used as a sole intervention)
remains dependent on the environmental force of trans-
mission in any given location.
SCORE’s randomizedoperational research studies onMDA
strategies are sufﬁciently large (25 villages per arm), such that
we can compare not only the treatment arms but also examine
individual village outcomes within arms. After three or four
annual MDAs, our data show that not all locations within an
TABLE 2
Concordance between approach 1 (the absolute change method) and approach 3 (the change in WHO risk category method) in classifying
persistent hotspots in 74 villages in Tanzania; Kappa = 0.35
Absolute change method (approach 1)
TotalDeclining Persistent hotspot
WHO risk categoriesmethod (approach3) Declining 34 21 55
Persistent hotspot 3 16 19
Total 37 37 74
WHO = World Health Organization. Villages that were classiﬁed as persistent hotspots by one approach and declining by the other approach are indicated in boldface.
TABLE 3
Concordancebetweenapproach2 (the percent changemethod) and approach3 (the change inWHO risk categorymethod) in classifying persistent
hotspots in 74 villages in Tanzania; Kappa = 0.63
Percent change method (approach 2)
TotalDeclining Persistent hotspot
WHO risk categoriesmethod (approach3) Declining 48 7 55
Persistent hotspot 4 15 19
Total 52 22 74
WHO = World Health Organization. Villages that were classiﬁed as persistent hotspots by one approach and declining by the other approach are indicated in boldface.
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arm demonstrate the expected decreases in prevalence and
intensity. We have termed these locations persistent hot-
spots. However, there are multiple potential ways that might
be used to deﬁne what constitutes a persistent hotspot. For
our purposes, we require a persistent hotspot to be a location
that has had multiple MDAs, as distinct from a location that
simply had high prevalence before intervention.
Clear deﬁnitionswill be essential for operational research on
persistent hotspots, both to try to determine why they exist
and todesignandevaluate strategies to “break” their apparent
resistance to control. Likewise, such deﬁnitions will be critical
for NTD program managers to help them achieve the goals of
their programs, and to help them reallocate their resources to
address persistent hotspotswhile reducing inputs in locations
that have been more responsive.
The analyses presented here show that the approach cho-
sen to deﬁne persistent hotspots and the thresholds used in
the context of these approaches can greatly inﬂuence the
number of persistent hotspots identiﬁed. For example, in
Approach 3, rather than using the currentWHO risk categories
of ³ 50–10% one might consider ³ 50–25% and ³ 25–10% as
break points to delineate persistent hotspots of acceptable
declines due to 3 years of MDA, thereby changing the desig-
nation of persistent hotspots considerably in some settings.
Likewise, the current presentations are based on results after
3 years of annual MDA. Different results might be likely if cal-
culations were based on monitoring after only one or two
MDAs. Besides the number of years of treatment, year-to-year
variations in transmission patterns, for example due to
ﬂooding or drought, can also havean impact. The year-to-year
variation is likely to be greater on prevalence than intensity
because infection with the few worm pairs needed to result in
a prevalent case would likely occur sooner than the time it
generally takes to accumulate enough worms to result in a
heavy infection.
In general, our preferences are for the use of Approaches 2
and 4, and this is based on Approach 2 taking starting prev-
alence into account, whereas Approach 4 allows parallel
consideration of intensity data when this parameter is avail-
able. However, if the starting prevalence is very similar among
all targeted locations, Approach1maybeadequate indeﬁning
the persistent hotspots. Approach 3, which is based on cur-
rent WHO guidelines, is problematic. Perhaps on their re-
vision, Approach 3 can be modiﬁed accordingly.
The goal of the current exercise is not to advocate for a
speciﬁc deﬁnition of a persistent hotspot. It is possible that
different deﬁnitionswill be developed in different contexts.We
have presented several possible ways to deﬁne these, in-
cluding an evaluation of how applying different deﬁnitions
might inﬂuence the evaluation of program impact. We did not
extensively explore the effects of varying prevalence and in-
tensity cutoffs, but it would be easy to use our data to evaluate
the impact of choosing different cutoffs from the oneswehave
selected. Whatever approach is used, it is critical that the user
clearly deﬁne the approach and cutoffs being used for analy-
sis. Only in that way can results of studies and program per-
formance be compared.
Another consideration when dealing with locations with
differences in prevalence and intensity is the sensitivity of the
mapping assays used to determine these parameters. For
example, the studies in Tanzania used Kato-Katz results to
assess prevalence. This test has low sensitivity in areas with
low prevalence. Were infection status measured with a more
sensitive assay, cutoffs used to deﬁne persistent hotspots
would need to be changed. For example, an assay with low
sensitivity will underestimate the true prevalence achieved
when moving from high prevalence to low prevalence,
resulting in categorizations as persistent hotspots. Thus, as
the sensitivities of assays improve new thresholds will need
to be deﬁned.
The results from our assessment of using coverage in de-
ﬁning persistent hotspots are counter-intuitive. One would
expect that if a village does not have adequate coverage, it
would likely be a persistent hotspot. However, in the dataset
used in this study, low coverage by the study deﬁnition was
substantial (most such villages hovering around 50% the ﬁrst
year and just below 75% in subsequent years). The analyses
indicate that at this level, coveragewas not the sole or primary
deﬁning predictor of being a persistent hotspot. This, of
course, does not mean that programs should not strive for the
best coverage they can achieve. Certainly, if programs have
universally poor coverage, onewould expect there to bemany
more and perhaps universal persistent hotspots. Our analy-
ses, however, focus attention on the importance of very local
factors in the transmission of schistosomiasis. Our working
hypothesis is that a persistent hotspot is a location that has a
high force of transmission, and thus, reinfection reliably oc-
curs after MDA. By contrast, we hypothesize that a location
that responds well by steadily declining in prevalence would
be where MDAs appreciably lower the force of transmission,
slowing the rate of reinfection.
Identiﬁcation of the factors responsible for the genesis of
persistent hotspots is the topic of two new SCORE studies.
Potential factors under consideration are general terrain; low
level of sanitation; limited use of sanitation; limited availability
of clean water; amount or seasonality of surface water; water
usage (agriculture/household); number, type, and location of
water contact sites; local abundance of snail habitat; snail
strains and their relative susceptibilities; genetic variation
among schistosomes; the presence of competitor or hybrid
schistosomes; genetic variation among exposed people;
variable drug effectiveness and variable levels of compliance
in taking the drug; and persistence of transmission because
of systematic noncompliance. The force of transmission is
clearly determined by multiple factors that in concert do or do
not facilitate reinfection after treatment.
In addition to accurately deﬁning persistent hotspots and
attempting to identify the factors that contribute to their ex-
istence, there is an urgent need to determine how an NTD
programmanager can successfully deal with them when they
occur. Deﬁning what interventions can change a persistent
hotspot into one that ismeaningfully decliningwill next require
TABLE 4
Proportion of Tanzanian study villages in study arms 1 (community-
wide treatment for 3 years), 2 (community-wide treatment for 2 years
followed by school-based treatment for 1 year), and 4 (school-
based treatment for 3 years) with adequate and inadequate treat-
ment coverage
Not adequate (%) Adequate coverage (%) Total (%)
Study arm 1 20 (83) 4 (17) 24 (100)
2 14 (56) 11 (44) 25 (100)
4 11 (44) 14 (56) 25 (100)
Total 45 (61) 29 (39) 74 (100)
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additional operational research. Possible approaches include
increases in PC, use of better drugs or drug combinations,
inclusion of snail control measures, and the application of
sanitation and the provision of clean water. However, in the
short term,many of these are not feasible or are not supported
politically.
Currently, it is not standard practice tomonitor the impact of
schistosomiasis MDA programs on a frequent basis. How-
ever, data from large studies such as ours clearly indicate that
response to MDA can vary considerably among nearby vil-
lages. It would be beneﬁcial to identify those locations that are
persistent hotspots as early as possible, especially if it would
allowmore intensive, targeted efforts in those locations. Such
evaluations would, in parallel, identify places that have
responded sufﬁciently to MDA, and might therefore require
less intensive efforts. However, at this time it seems such
characterizations can only be made after at least some MDA.
With the use of new point-of-care mapping tools, it may be
possible tomove tomore frequentmonitoring and thus detect
persistent hotspots sooner. Being able to empirically deﬁne
persistent hotspots would hopefully ensure that resources for
more intensive intervention are distributed in locations that
need them the most.
The current studywasbasedondata from theSCOREstudy
in Mwanza, Tanzania. This is a generally high-prevalence
setting. The same pattern of variable response to MDA is
apparent in all the multiyear randomized SCORE trials, in-
cluding in those starting at low prevalence levels.9 Developing
strategies for deﬁning, identifying, and addressing persistent
hotspots for places with a broad range of prevalence rates will
be critical if morbidity control and eventually elimination is to
be achieved.
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